Accumulation of CD 133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation Clinical article

作者：Tamura Kaoru; Aoyagi Masaru^*; Wakimoto Hiroaki; Ando Noboru; Nariai Tadashi; Yamamoto Masaaki; Ohno Kikuo

来源：Journal of Neurosurgery, 2010, 113(2): 310-318.

DOI：10.3171/2010.2.JNS091607

• cancer stem cell
• CD133
• Gamma Knife surgery
• malignant glioma
• radioresistance
• tumor blood vessels

Object. Recent evidence suggests that a glioma stem cell subpopulation might contribute to radioresistance in malignant gliomas. To investigate this hypothesis, the authors examined recurrent malignant gliomas for histopathological changes after high-dose irradiation with Gamma Knife surgery (GKS) and external beam radiation therapy (EBRT).
Methods. Thirty-two patients with malignant gliomas (Grade 3 in 8 patients, Grade 4 in 24) underwent GKS in combination with EBRT. Serial MR and L-[methyl-(11)C] methionine PET images were employed to assess remnant or recurrent tumors after GKS. Twelve patients underwent surgical removal after GKS and EBRT. Histological sections were subjected to immunohistochemistry for MIB-1, factor VIII, and stem cell markers, nestin and CD133.
Results. The site of GKS treatment failure was local in 16 (76.2%) of 21 patients with glioblastomas showing progression; in 9 of these 16 patients, the recurrence clearly arose within the target lesion of GKS. Histopathological examination after GKS and EBRT showed variable mixtures of viable tumor tissues and necrosis. Viable tumor tissues exhibited high MIB-1 indices but reduced numbers of tumor blood vessels. There was marked accumulation of CD133-positive glioma cells, particularly in remnant tumors within the necrotic areas, in sections obtained after GKS plus EBRT, whereas CD133-positive cells appeared very infrequently in primary sections prior to adjuvant treatment.
Conclusions. The results indicate that CD 133-positive glioma stemlike cells can survive high-dose irradiation, leading to recurrence, despite prolonged damage to tumor blood vessels. This could be an essential factor limiting the effectiveness of GKS plus EBRT for malignant gliomas. (DOI: 10.3171/2010.2.JNS091607)

• 出版日期2010-8